Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2023-04-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司股东回报规划（2023年-2025年）
Regulatory Filings Classification · 90% confidence The document is titled '股东回报规划(2023 年-2025 年)' which translates to 'Shareholder Return Plan (2023-2025)'. It details the company's profit distribution policy, dividend conditions, distribution ratios, and governance procedures related to shareholder returns over a multi-year period. The content focuses on the company's dividend policy and shareholder return strategy rather than announcing a specific dividend amount or payment date. It is not a short announcement or a certification but a detailed policy document. This fits best under the category of Notice of Dividend Amount (DIV) if it were announcing specific dividends, but since it is a planning document outlining the dividend policy and shareholder return framework, it is more aligned with a Regulatory Filing (RNS) as it does not fit neatly into other categories like Dividend Notice or Annual Report. The document is also under 5,000 characters and does not announce a report publication, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2023-04-10 Chinese
哈药集团股份有限公司2022年度利润分配预案的公告
Notice of Dividend Amount Classification · 90% confidence The document is an announcement regarding the 2022 annual profit distribution plan of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It states that the company will not distribute profits or convert capital reserves into shares for the year 2022 due to negative distributable profits. The document includes details about the board meeting approval, independent directors' opinions, and supervisory board opinions, and it mentions that the plan will be submitted to the 2022 annual shareholders' meeting for approval. The document is relatively short (1077 characters) and serves as a formal announcement of a dividend-related decision rather than a full financial report or detailed dividend notice. It does not contain actual financial statements or detailed dividend payment information but rather the profit distribution proposal and related procedural information. Therefore, it fits best as a Notice of Dividend Amount (DIV) announcement, as it relates to the company's dividend distribution plan for the year.
2023-04-10 Chinese
哈药集团股份有限公司2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "2022 年年度报告摘要" which translates to "2022 Annual Report Summary". It contains detailed financial data for the year 2022, including profit, revenue, assets, and shareholder information. It also includes management discussion on business operations, industry conditions, and company strategy. The length is 7875 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. The presence of audited financial figures and comprehensive business overview aligns with the characteristics of an Annual Report (10-K). Therefore, this document is classified as an Annual Report (10-K). FY 2022
2023-04-10 Chinese
哈药集团股份有限公司2022年度财务报表审计报告
Regulatory Filings
2023-04-10 Chinese
哈药集团股份有限公司独立董事关于公司九届三十五次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various company matters discussed at the 35th meeting of the 9th board of directors of Harbin Pharmaceutical Group Co., Ltd. It includes opinions on profit distribution, appointment of auditors, asset impairment, related party transactions, senior management performance indicators, directors and officers liability insurance, internal control evaluation, and shareholder return plans. The content is focused on governance, compliance with laws and regulations, and board meeting resolutions rather than financial statements or audit reports themselves. The document is not a full annual report, audit report, or financial statement, but rather a governance-related opinion document from independent directors. Therefore, it fits best under Board/Management Information (MANG). The document length is 2468 characters, which is relatively short and consistent with a board opinion or announcement rather than a full report.
2023-04-10 Chinese
哈药集团股份有限公司关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (Beijing Xinghua Certified Public Accountants) for auditing the company's 2023 financial statements and internal control audit. It details the qualifications, independence, and audit fees of the firm, as well as the approval process by the board and independent directors. The document does not contain any actual financial statements or audit reports but is a formal announcement of the intention to reappoint the auditor, pending shareholder approval. The document length is under 5,000 characters and is clearly an announcement rather than the audit report itself. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement about auditor appointment, not an Audit Report (AR) or Annual Report (10-K).
2023-04-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.